Champignon Closes AltMed Transaction, Partners With Leading Canadian Pharmacy

Champignon Brands (CSE: SHRM) today announced that it has partnered with a major pharmacy chain within Canada to dispense its ketamine topical prescription product throughout the network. While the pharmacy chain was not addressed by name, it is said to be one of the leading chains within the country.

Under the arrangement, Champignon will see the pharmacy perform central fill and compounding functions for the firms proprietary ketamine formulations at one location. The products will then be distributed as needed throughout the pharmacies network of locations. Champignon will be utilizing this network to also distribute its products to numerous medical and pain and addiction clinics throughout the nation.

In connection with the arrangement, Champignon and the pharmacy have begun to design a custom level “B” clean room which will be used to compound and package the ketamine formulations, which is expected to be completed by the third quarter of 2020. Such formulations include off-market intranasal esketamine and ketamine topicals.

“With this arrangement, Champignon boasts complete vertical integration with respect to our rapid onset ketamine treatments and therapies. From novel formulations to product development at a purpose-built GMP and DIN licensed pharmaceutical facility, and now automated prescription fulfillment and on-site compounding infrastructure, we have managed to capture the entire product lifecycle.”
Gareth Bridsall, CEO

Outside the developments of Champignon’s ketamine formulations, the company also announced that it has closed the transaction with that of AltMed Capital Corp. AltMed operates a ketamine clinic in Ontario known as the Canadian Rapid Treatment Centre of Excellence (CRTCE), for which it recently acquired 100% of, in addition to being a psychedelic medicine IP aggregator and novel drug discoverer.

Champignon currently intends to open five additional ketamine clinics across North America by the fourth quarter of 2020, with locations planned for New York, California, and Florida.

Champignon Brands last traded at $0.88 on the CSE.


FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

Agnico Q1 Earnings Results Overshadowed By A Sinking Gold Price

Why More People Are Starting to Feel Broke | Darrell Thomas – VRIC Media

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

Recommended

Selkirk Copper Strikes New Lens Beneath Old Pit, Launches 50,000 Metre Phase 2 Program

Silver47 Pulls High-Grade Gold and Silver Assays from Nevada Vein Network At Kennedy

Related News

Champignon Brands To Change Name To Braxia Scientific

Champignon Brands (CSE: SHRM) is evidently looking to turn a new leaf, with the company...

Monday, May 3, 2021, 07:16:21 AM

Champignon Brands To Acquire Biotech Firm Novo Formulations

Champignon Brands (CSE: SHRM) announced today that they have signed a definitive agreement to acquire...

Thursday, March 19, 2020, 03:27:32 PM

Champignon Brands Appoints Dr Joseph Gabriele To Special Advisory Committee

Champignon Brands (CSE: SHRM) this morning announced that it is bolstering its special advisory committee...

Wednesday, March 25, 2020, 08:57:50 AM

Braxia Scientific Launches Multiple-Dose Psilocybin Clinical Trial for Treatment-Resistant Depression

Braxia Scientific Corp. (CSE: BRAX), formerly Champignon Brands, announced today that its clinical research and...

Friday, August 27, 2021, 08:20:00 AM

Champignon Brands Vs Mind Medicine: A Comparison

Champignon Brands (CSE: SHRM), prior to the public listing of the company, had a primary...

Monday, April 20, 2020, 09:01:13 AM